Glucarpidase
Carboxypeptidase — VARIOUS
Also known as: glucarpidase (genetical recombination), megludase, voraxaze
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Glucarpidase is a drug in the Carboxypeptidase class catalogued in DrugCentral. It was first approved by the FDA in 2012. Recorded indications include Toxic plasma methotrexate concentration reduction.
- Drug class: Carboxypeptidase.
- Indications: Toxic plasma methotrexate concentration reduction.
- ATC code: V03AF09 (Detoxifying agents for antineoplastic treatment).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Toxic plasma methotrexate concentration reduction
Mechanism & targets
| Established pharmacologic class | Carboxypeptidase |
|---|
Regulatory approvals (3)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2022-01-11 | EMA | — | SERB SAS | Yes |
| 2021-09-27 | PMDA | — | OHARA PHARMACEUTICAL CO., LTD | Yes |
| 2012-01-17 | FDA | — | BTG INTERNATIONAL INC | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
V03AF09 | VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Detoxifying agents for antineoplastic treatment |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Laboratory test interference | 347.9 |
| Underdose | 124.4 |
| Rebound effect | 118.9 |
| False positive investigation result | 95.9 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 9074-87-7 |
| InChIKey | — |
| PubChem CID | 21195079 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Glucarpidase used for?
DrugCentral lists the following indications for Glucarpidase: Toxic plasma methotrexate concentration reduction.
When was Glucarpidase first approved?
Glucarpidase was first approved by the FDA in 2012.
What drug class does Glucarpidase belong to?
Glucarpidase is in the Carboxypeptidase class.
Browse: all drugs starting with G · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5138 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1863515 — compound record and bioactivity
- PubChem CID 21195079 — chemical identifiers
- DrugBank DB08898 — drug record
- FDA UNII 2GFP9BJD79 — substance identity
- DailyMed: FDA labels for Glucarpidase — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.